Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab Combo in Advanced Cervical Cancer
NCT03912402Phase 2Unknown
- Sponsor
- BIOCAD
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prolgolimab in Cervical Cancer (CC), sponsored by BIOCAD. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
prolgolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03912402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912402.